Neratinib in Adjuvant Treatment of Patients With HER2-positive Breast Cancer — Less Is More?

Oncology in Clinical Practice - Poland
doi 10.5603/ocp.2019.0014
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

VM Media SP. zo.o VM Group SK

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy